ProQinase GmbH was founded in 2001 as a subsidiary of the Tumor Biology Center Freiburg. This cancer center combined excellent research with exceptional patient care under one roof. Initially, ProQinase was established in order to support funding of the Tumor Biology Center´s in-house anti-cancer drug development by marketing research tools and test systems. Today, ProQinase is a leading contract research organization (CRO) for drug discovery in oncology.
From 2015 to 2017 ProQinase was owned by a Chinese private equity fund.
In February 2019 ProQinase was purchased by Reaction Biology Corporation (RBC) (www.reactionbiology.com), located in Malvern, PA. RBC is a leader in early stage drug-discovery services, with a heavy focus on kinase and epigenetic drug targets for both biochemical and cell-based assays.
The combination of RBC and ProQinase will create the world's leading kinase drug discovery company, with a diverse offering and operations in Europe and the Unted States.